Ambu CEO Britt Meelby Jensen has scrapped half the Danish medtech company’s development projects under a new strategy, which will also halve future launches – but she won’t say which ones are out.
by ulrich quistgaard, translated by daniel pedersen
Under Ambu’s new strategy, Zoom In, the company will concentrate on fewer products, fewer customers, and fewer markets going forward, says Chief Executive Officer Britt Meelby Jensen. Half of the current development projects have been shelved.
In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.
The US retail chain has stopped selling its own private label hearing aids – and until the next generation comes along, other hearing companies selling products via Costco are enjoying the empty shelf space.